Product Information
VENLAFAXINE HCL 37.5 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.0714 per EA under NDC 68382001901. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 13, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382001901
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077653FDA Approved
6/13/2008
TE Code
AB
On Market Since
6/13/2008
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL 37.5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 76.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0714 per EA |
|---|---|
| All-time high | $0.4135 (Jan 13, 2016) |
| All-time low | $0.0609 (May 22, 2024) |
| 52-week high | $0.0822 |
| 52-week low | $0.0714 |
| Median price | $0.1586 |
| Average price | $0.1725 |
| Largest weekly change | +58.7% (Jun 19, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Venlafaxine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL 37.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL 37.5 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.0714 per EA (NDC 68382001901), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL 37.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL 37.5 MG TABLET has declined 76.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL 37.5 MG TABLET?
Since Nov 28, 2013, the NADAC for VENLAFAXINE HCL 37.5 MG TABLET has ranged from a low of $0.0609 (May 22, 2024) to a high of $0.4135 (Jan 13, 2016), with a median of $0.1586 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL 37.5 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as VENLAFAXINE HCL 37.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures VENLAFAXINE HCL 37.5 MG TABLET?
VENLAFAXINE HCL 37.5 MG TABLET (NDC 68382001901) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.